HFS
CPRX

Hantz Financial Services’s Catalyst Pharmaceutical CPRX Stock Holding History

Hantz Financial Services’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98K Buy
3,107
+167
+6% +$4.93K ﹤0.01% 1393
2026
Q1 		$73K Buy
2,940
+518
+21% +$12.3K ﹤0.01% 1408
2025
Q4 		$57K Buy
2,422
+1,890
+355% +$42.1K ﹤0.01% 1381
2025
Q3 		$10K Buy
532
+157
+42% +$3.23K ﹤0.01% 1825
2025
Q2 		$8K Buy
375
+372
+12,400% +$8.78K ﹤0.01% 1573
2025
Q1 		$0 Buy
+3
New +$68 ﹤0.01% 1731

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hantz Financial Services's CPRX Position: Q2 2026 in Review

Hantz Financial Services increased its Catalyst Pharmaceutical (CPRX) stake by 5.7% in Q2 2026, buying an estimated $4.93K and bringing the position to 3,107 shares worth $98K. The position accounts for ﹤0.01% of the portfolio, ranked #1393.

Hantz Financial Services first reported a position in CPRX in Q1 2025 and has held it in 6 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Hantz Financial Services held 3,107 shares of Catalyst Pharmaceutical worth $98K as of Q2 2026.
  • Hantz Financial Services bought 167 Catalyst Pharmaceutical shares in Q2 2026, an estimated $4.93K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2026, its #1393 holding.
  • Hantz Financial Services first reported a position in Catalyst Pharmaceutical in Q1 2025 and has held it in 6 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.